Rexahn Pharmaceutic * RNN * // stark unterbewerteter Biotech-Wert a.d. Krebsforschung ? - 500 Beiträge pro Seite
eröffnet am 11.02.10 21:25:46 von
neuester Beitrag 19.01.12 20:22:35 von
neuester Beitrag 19.01.12 20:22:35 von
Beiträge: 31
ID: 1.155.923
ID: 1.155.923
Aufrufe heute: 0
Gesamt: 3.772
Gesamt: 3.772
Aktive User: 0
ISIN: US7616403090 · WKN: A2PHDT
1,8100
USD
-3,21 %
-0,0600 USD
Letzter Kurs 06.11.20 NYSE
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 3,0920 | +22,21 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 15,550 | -17,02 | |
| 9,7200 | -19,60 | |
| 0,9250 | -23,55 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Feedback
Hallo,
kennt jemand diesen Titel ? Bis jetzt noch kaum gehandelt in Deutschland. Knapp 20% im Plus an der Wallstreet.
Habe einen Artikel gefunden, in dem es heißt, daß "3 Blockbuster Medikamente" in der Pipeline des Unternehmens sein könnten. Da noch unter 1$, könnte ein Einstieg noch lohnen ? Gibt es Meinungen dazu ?
Quelle: http://www.baystreet.ca/users/newswire/viewarticle.aspx?id=3…
Bin neben diesen Wert auch auf BIODEL gestoßen, der bis data auch noch nicht hier diskutiert wurde...
#################################################################
Rexahn Pharmaceuticals could have 3 blockbusters. Currently trades under $1
2/10/2010 (BAYSTREET NEWSWIRE)
On January 21st, 1990, the founder of Rexahn Pharmaceuticals (Amex: RNN) lost his sister to stomach cancer. What came of that tragedy has become a rare find in the space of thousands of publicly traded biotechnology and health care companies. A remarkable find that has gone almost completely undiscovered by most investors until now.
In short, this is a clinical stage biopharmaceutical company trading under a dollar on a major exchange (AMEX), with multiple catalysts to help its share price move significantly higher in the short term (this quarter), but as we dive deeper we see that there is so much more here. In fact it will require several articles to truly cover some of the amazing potential in the treatments and drugs in the company's pipeline. Three of those drugs have been labled potential blockbusters that have several big pharmaceutical companies lining up as interested partners.
In fact, already one partner- Teva Pharmaceuticals- signed a development & commercialization agreement for RX-3117; a novel anti-cancer compound last September.
Teva, the world's biggest generics pharmaceutical company in the world, is scheduled to drop millions of dollars worth of milestone payments into this small but promising company's coffers this year alone. If two of those milestones- which are scheduled to take place around mid-year- are indeed reached as planned, RNN will receive around $4 million. In addition, according to contractual obligations Teva will also be forced to make an additional multi-million dollar investment into the company at 20% above market prices. The higher the shares are trading at that point, the higher the influx of capital from Teva's investment will be.
When it comes down to it, my "biotech geek squad" and I have been digging and researching this company since we stumbled upon it weeks ago and frankly, we felt a need to somewhat rush this report out for our readers. When we found out the company was doing a presentation at the12th Annual BIO CEO & Investor Conference at The Waldorf Astoria, in New York City this week, we knew then that it wouldn't remain undiscovered for long so we wanted you to beat the crowds and stake your claim of shares. And as you'll see, these are definitely shares you may want to hold on to.
The company, Rexahn, is named after Chang Ahn the doctor who founded the company after he saw his sister pass away due to cancer.
Prior to founding Rexahn, he held dual positions as both Expert Regulatory Officer and Laboratory Chief at the FDA Center for Drug Evaluation and Research.
"(My sister) was four years older than I and we were very close," Dr. Ahn explains. "At the time I was at the FDA and prior to that I was at the National Cancer Institute. My background was in cancer research and I had a vast network of prominent clinicians, you know?
"And all those friends and all my network contacts couldn't help my sister. Through my sister's struggle, seeing her last stage suffering from stomach cancer, that was devastating.
"Before that time I was confident that I was a good cancer researcher. But after that, I was really humbled. It was at that moment, that I decided to develop drugs toward the cure side, rather than just treating the illness. In fact, I prepared myself at the FDA because that is a really good place to learn how to develop drugs and I was able to gain lots of knowledge during my time there. Drug development is a multi-faceted art, actually, so I picked up lots of necessary skills and information. About ten years later, I was finally ready to start my own journey and that's when we started the company."
Dr. Ahn is an internationally recognized drug development expert in the therapeutic areas of cancer and other life-threatening diseases. He has over 20 years of scientific experience in pharmacology and biotechnology fields.
Since they founded the company, they now have 8 oncology drugs in the pre-clinical stage and also have three very interesting and unique drug discovery platforms that support the company's goals to generate first-in-class or potentially market leading products. Those breakthrough products have successfully completed the phase 2a or proof of concept phase. That makes those products very viable licensing targets for product hungry pharmaceutical companies.
RNN also has "multi-indication" therapeutics that positions it for long-term success. Their three market leading compounds have all shown excellent safety profiles and we will likely have to come back and talk about each of these at length in order to fully communicate just how ground-breaking these treatments truly are:
Serdaxin is a game-changing mood disorder drug in a huge market filled with major players (Pfizer, Eli-Lilly, Glaxo). It is being developed to treat depression and mood disorders. It is a dual enhancer of serotonin and dopamine levels in the brain. It has a mechanistic action unique from the widely used antidepressants called selective serotonin re-uptake inhibitors (SSRIs or SNRIs). These SSRIs/SNRIs may be effective in treating the negative mood state, but may not be effective in depression resulting from loss of positive mood state. There are high unmet needs in treating depression, including the need for drugs with faster onset of action, greater efficacy, and minimum side effects. Among antidepressants, SSRIs/SNRIs appear to be the leading therapy, but are only partially effective and have a 50% estimated response rate and up to 30% relapse rate. Serdaxin aims to change all of that.
In the next 4 years over $5 billion of the $11 billion anti-depressant market will come off patent protection and it means that RNN has perhaps the best shot at replacing those compounds and expanding the market for patients who did not do well on prozac or zoloft. In addition it appears Serdaxin also is a neuroprotector for Central Nervous System Disorders. Already there are some strong indications that its neuroprotector properties could help treat Parkinson's and Alzheimer’s diseases when detected early. If a partner is announced for this drug- as the company hopes- the stock price will rise dramatically and clinical trials for those two ailments would kick off as soon as this year.
Zoraxel for erectile dysfunction is a CNS-based sexual dysfunction drug that simultaneously enhances the levels of both serotonin and dopamine neurotransmitters in the brain. It is being developed as the first sexual dysfunction (SD) drug to have effects on all three phases of sexual activities, i.e., sexual motivation, erection and release. The company's initial focus will be male sexual dysfunction markets such as erectile dysfunction (ED) and and premature ejaculation (PE), but the drug is also showing some strong future applications in female sexual dysfunctions as well. Unlike Viagra and other SD drugs who only address blood flow issues, Zoraxel "makes you want to have sex." Keep in mind also that roughly half the patients who suffer from SD do not respond to Viagra. This drug candidate is also has multi-billion dollar blockbuster potential.
Archexin for Cancer: A first-in-class AKT Inhibitor for glioblastoma, pancreatic, stomach, ovarian, & renal cell cancers, as well as other solid tumors. Incredibly, the FDA granted orphan drug status in all 5 tumor types for this drug. It significantly reduces production of AKT protein via inhibition of AKT mRNA.
In preclinical studies, ArchexinTM significantly reduced AKT in cancer cells of many human solid tumors. Once again, a multi-billion dollar blockbuster in the making.
The company has a proprietary drug development platform addressing multiple disease indications which have incredible value as "separate businesses" to many other drug companies. This is yet another indication that the technology at RNN is very deeply seeded. In fact, some analysts who have looked at the company think that there is "too much here" for the company to develop on their own, so these drug development platforms could become a revenue generating backbone whose pieces could be licensed off to many companies throughout the pharmaceutical industry.
A testament to the science may be found in the fact that one of the top shareholders in the company is a top 5 pharmaceutical company in Korea. The company is said to own 9% of the outstanding shares.
Another investor is the largest Pharmacy Chain in Korea- which owns and manages 1500 pharmacies throughout the country. They own 20% of the shares.
Among the ranks of some of the bigger investors in the company, you will also find KT&G, originally the "Korea Tobacco & Ginseng Corporation." A leading tobacco company in South Korea with sales over two billion US dollars per annum yielding significant profits on a consistent basis. The company sees them as a very important long-term investor whose collaboration runs deep. They also own roughly 9% of the shares.
"These are very unique investors," says Dr. Ahn whose family owns 50% of the company's outstanding shares. "That's one of the main reasons we didn't need venture capital money early on."
Those "closely held" investors account for holding 88% of the company's outstanding shares and by all indications, they are in it for the long haul.
With catalysts and developments like the company plans to file INDs for Serdaxin (PD) and Archexin (ovarian cancer) this year, it may make sense for you to become a long term investor as well.
As always, do your own DD.
[M.E. Garza covers the biotech and healthcare sector of the market]
Disclosure: LONG RNN
######
kennt jemand diesen Titel ? Bis jetzt noch kaum gehandelt in Deutschland. Knapp 20% im Plus an der Wallstreet.
Habe einen Artikel gefunden, in dem es heißt, daß "3 Blockbuster Medikamente" in der Pipeline des Unternehmens sein könnten. Da noch unter 1$, könnte ein Einstieg noch lohnen ? Gibt es Meinungen dazu ?
Quelle: http://www.baystreet.ca/users/newswire/viewarticle.aspx?id=3…
Bin neben diesen Wert auch auf BIODEL gestoßen, der bis data auch noch nicht hier diskutiert wurde...
#################################################################
Rexahn Pharmaceuticals could have 3 blockbusters. Currently trades under $1
2/10/2010 (BAYSTREET NEWSWIRE)
On January 21st, 1990, the founder of Rexahn Pharmaceuticals (Amex: RNN) lost his sister to stomach cancer. What came of that tragedy has become a rare find in the space of thousands of publicly traded biotechnology and health care companies. A remarkable find that has gone almost completely undiscovered by most investors until now.
In short, this is a clinical stage biopharmaceutical company trading under a dollar on a major exchange (AMEX), with multiple catalysts to help its share price move significantly higher in the short term (this quarter), but as we dive deeper we see that there is so much more here. In fact it will require several articles to truly cover some of the amazing potential in the treatments and drugs in the company's pipeline. Three of those drugs have been labled potential blockbusters that have several big pharmaceutical companies lining up as interested partners.
In fact, already one partner- Teva Pharmaceuticals- signed a development & commercialization agreement for RX-3117; a novel anti-cancer compound last September.
Teva, the world's biggest generics pharmaceutical company in the world, is scheduled to drop millions of dollars worth of milestone payments into this small but promising company's coffers this year alone. If two of those milestones- which are scheduled to take place around mid-year- are indeed reached as planned, RNN will receive around $4 million. In addition, according to contractual obligations Teva will also be forced to make an additional multi-million dollar investment into the company at 20% above market prices. The higher the shares are trading at that point, the higher the influx of capital from Teva's investment will be.
When it comes down to it, my "biotech geek squad" and I have been digging and researching this company since we stumbled upon it weeks ago and frankly, we felt a need to somewhat rush this report out for our readers. When we found out the company was doing a presentation at the12th Annual BIO CEO & Investor Conference at The Waldorf Astoria, in New York City this week, we knew then that it wouldn't remain undiscovered for long so we wanted you to beat the crowds and stake your claim of shares. And as you'll see, these are definitely shares you may want to hold on to.
The company, Rexahn, is named after Chang Ahn the doctor who founded the company after he saw his sister pass away due to cancer.
Prior to founding Rexahn, he held dual positions as both Expert Regulatory Officer and Laboratory Chief at the FDA Center for Drug Evaluation and Research.
"(My sister) was four years older than I and we were very close," Dr. Ahn explains. "At the time I was at the FDA and prior to that I was at the National Cancer Institute. My background was in cancer research and I had a vast network of prominent clinicians, you know?
"And all those friends and all my network contacts couldn't help my sister. Through my sister's struggle, seeing her last stage suffering from stomach cancer, that was devastating.
"Before that time I was confident that I was a good cancer researcher. But after that, I was really humbled. It was at that moment, that I decided to develop drugs toward the cure side, rather than just treating the illness. In fact, I prepared myself at the FDA because that is a really good place to learn how to develop drugs and I was able to gain lots of knowledge during my time there. Drug development is a multi-faceted art, actually, so I picked up lots of necessary skills and information. About ten years later, I was finally ready to start my own journey and that's when we started the company."
Dr. Ahn is an internationally recognized drug development expert in the therapeutic areas of cancer and other life-threatening diseases. He has over 20 years of scientific experience in pharmacology and biotechnology fields.
Since they founded the company, they now have 8 oncology drugs in the pre-clinical stage and also have three very interesting and unique drug discovery platforms that support the company's goals to generate first-in-class or potentially market leading products. Those breakthrough products have successfully completed the phase 2a or proof of concept phase. That makes those products very viable licensing targets for product hungry pharmaceutical companies.
RNN also has "multi-indication" therapeutics that positions it for long-term success. Their three market leading compounds have all shown excellent safety profiles and we will likely have to come back and talk about each of these at length in order to fully communicate just how ground-breaking these treatments truly are:
Serdaxin is a game-changing mood disorder drug in a huge market filled with major players (Pfizer, Eli-Lilly, Glaxo). It is being developed to treat depression and mood disorders. It is a dual enhancer of serotonin and dopamine levels in the brain. It has a mechanistic action unique from the widely used antidepressants called selective serotonin re-uptake inhibitors (SSRIs or SNRIs). These SSRIs/SNRIs may be effective in treating the negative mood state, but may not be effective in depression resulting from loss of positive mood state. There are high unmet needs in treating depression, including the need for drugs with faster onset of action, greater efficacy, and minimum side effects. Among antidepressants, SSRIs/SNRIs appear to be the leading therapy, but are only partially effective and have a 50% estimated response rate and up to 30% relapse rate. Serdaxin aims to change all of that.
In the next 4 years over $5 billion of the $11 billion anti-depressant market will come off patent protection and it means that RNN has perhaps the best shot at replacing those compounds and expanding the market for patients who did not do well on prozac or zoloft. In addition it appears Serdaxin also is a neuroprotector for Central Nervous System Disorders. Already there are some strong indications that its neuroprotector properties could help treat Parkinson's and Alzheimer’s diseases when detected early. If a partner is announced for this drug- as the company hopes- the stock price will rise dramatically and clinical trials for those two ailments would kick off as soon as this year.
Zoraxel for erectile dysfunction is a CNS-based sexual dysfunction drug that simultaneously enhances the levels of both serotonin and dopamine neurotransmitters in the brain. It is being developed as the first sexual dysfunction (SD) drug to have effects on all three phases of sexual activities, i.e., sexual motivation, erection and release. The company's initial focus will be male sexual dysfunction markets such as erectile dysfunction (ED) and and premature ejaculation (PE), but the drug is also showing some strong future applications in female sexual dysfunctions as well. Unlike Viagra and other SD drugs who only address blood flow issues, Zoraxel "makes you want to have sex." Keep in mind also that roughly half the patients who suffer from SD do not respond to Viagra. This drug candidate is also has multi-billion dollar blockbuster potential.
Archexin for Cancer: A first-in-class AKT Inhibitor for glioblastoma, pancreatic, stomach, ovarian, & renal cell cancers, as well as other solid tumors. Incredibly, the FDA granted orphan drug status in all 5 tumor types for this drug. It significantly reduces production of AKT protein via inhibition of AKT mRNA.
In preclinical studies, ArchexinTM significantly reduced AKT in cancer cells of many human solid tumors. Once again, a multi-billion dollar blockbuster in the making.
The company has a proprietary drug development platform addressing multiple disease indications which have incredible value as "separate businesses" to many other drug companies. This is yet another indication that the technology at RNN is very deeply seeded. In fact, some analysts who have looked at the company think that there is "too much here" for the company to develop on their own, so these drug development platforms could become a revenue generating backbone whose pieces could be licensed off to many companies throughout the pharmaceutical industry.
A testament to the science may be found in the fact that one of the top shareholders in the company is a top 5 pharmaceutical company in Korea. The company is said to own 9% of the outstanding shares.
Another investor is the largest Pharmacy Chain in Korea- which owns and manages 1500 pharmacies throughout the country. They own 20% of the shares.
Among the ranks of some of the bigger investors in the company, you will also find KT&G, originally the "Korea Tobacco & Ginseng Corporation." A leading tobacco company in South Korea with sales over two billion US dollars per annum yielding significant profits on a consistent basis. The company sees them as a very important long-term investor whose collaboration runs deep. They also own roughly 9% of the shares.
"These are very unique investors," says Dr. Ahn whose family owns 50% of the company's outstanding shares. "That's one of the main reasons we didn't need venture capital money early on."
Those "closely held" investors account for holding 88% of the company's outstanding shares and by all indications, they are in it for the long haul.
With catalysts and developments like the company plans to file INDs for Serdaxin (PD) and Archexin (ovarian cancer) this year, it may make sense for you to become a long term investor as well.
As always, do your own DD.
[M.E. Garza covers the biotech and healthcare sector of the market]
Disclosure: LONG RNN
######
Schlusstand 0,92 $ - Nachbörslich geht´s aber weiter nach oben. Aktell 0,98 $, siehe http://www.marketwatch.com/investing/stock/RNN 
Marktkap. bei 70 Mio.$. Falls das mit den 3 Blockbustern wirklich was wird, könnte das dann ein weiterer "Tenbagger" wie Dendreon, Vermillion, etc. werden.
Marktkap. bei 70 Mio.$. Falls das mit den 3 Blockbustern wirklich was wird, könnte das dann ein weiterer "Tenbagger" wie Dendreon, Vermillion, etc. werden.
Antwort auf Beitrag Nr.: 38.930.514 von yxcv1234 am 11.02.10 22:43:02Vorbörslich sind wir gearde bei 1$. Hoffentlich geht´s später weiter nach oben.
Antwort auf Beitrag Nr.: 38.934.744 von yxcv1234 am 12.02.10 15:11:11Aktuell schon 1,10 $ bei 500.000 gehandelten Aktien. Das macht Spaß ! Bin gestern noch rechtzeitig rein.
Antwort auf Beitrag Nr.: 38.935.053 von yxcv1234 am 12.02.10 15:38:12Geile Sache ! Langsam kann man mal ans erste Gewinne mitnehmen denken, 50% Kursanstieg in 2 Tagen 
Trading Spotlight
Antwort auf Beitrag Nr.: 38.936.202 von yxcv1234 am 12.02.10 17:35:14Bereits 7000 Stk. wurden heute in Frankfurt gehandelt, so viele wie noch nie ! Scheint langsam aus dem Dornröschenschlaf zu erwachen.
Gewinne mitnehmen? Ja, ab 2 oder 3 Eu 
Mal sehen, vielleicht auch erst ab 4 
Mal sehen, vielleicht auch erst ab 4 
Antwort auf Beitrag Nr.: 38.929.881 von yxcv1234 am 11.02.10 21:25:46hab den bericht auch gelesen und einfach mal welche aus dem bauch raus gekauft. denke mal könnte was gehen.... vielleicht
Antwort auf Beitrag Nr.: 38.945.804 von havefun64 am 15.02.10 15:30:50ja sehr interessant.
bin auch drin.
denke evtl. heute die 1,50 $
bin auch drin.
denke evtl. heute die 1,50 $
sie will höher.
denke man wird sie über 1,40 $ bringen.
denke man wird sie über 1,40 $ bringen.
na was sage ich
gap bei 0,98 usd... die amis neigen stark dazu ihre gaps schliessen zu wollen. hoffe so in diesem falle auch. will nochmal günstig rein...
Beeindruckender Kursverlauf! Wenn ich mir den Chart so anschaue, fällt natürlich gleich Mai 2009 auf. Das Problem bei raketenartig steigenden Kursen ohne Erholung oder Settlement ist, dass sie kaum Nachhaltigkeit besitzen. Es werden keine Unterstützungen gebildet die fallende Kurse wieder auffangen. Aber wahrscheinlich spekulieren die meisten eh nur auf den schnellen Gewinn. Ich geh davon aus, dass es bald genauso schnell wieder in die andere Richtung gehen wird. Solange viel Glück an euch alle!
~hopelessly
~hopelessly
Antwort auf Beitrag Nr.: 38.955.858 von hopelessly am 17.02.10 00:52:45Da stimme ich Dir zu. Bin deshalb auch wieder raus, um die Gewinne nicht gleich wieder zu verlieren. Immerhin findet man nur die eine Empfehlung, daß sie 3 mögliche Blockbuster im Programm haben. Bis diese aber in Phase 3 bzw. im Genehmigungsverfahren sind können noch paar Jahre ins Land gehen. Kurs wird vermutlich wieder deutlich nach unten gehen, falls nicht doch noch in Kürze offizielle News direkt von RNN kommen.
Antwort auf Beitrag Nr.: 38.959.688 von Vespaholic am 17.02.10 15:36:04Press Release Source: Rexahn Pharmaceuticals, Inc. On Wednesday February 17, 2010, 8:00 am EST
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2010.
“With our advancing clinical programs and robust pipeline of compounds for cancers and CNS-based disorders, such as Parkinson’s, Alzheimer’s, depression and sexual dysfunction, Rexahn is extremely well positioned to lead in the development of novel therapeutics for these disorders,” said Dr. Chang Ahn, CEO of Rexahn. “We look forward to continuing to expand our clinical programs and reporting data in 2010, bringing us closer to helping these patients in need.”
"These goals build on our successes in 2009, during which we announced positive clinical results for two of our lead clinical drug candidates, Serdaxin in Major Depressive Disorder (MDD) and Zoraxel for male sexual dysfunction, and we entered into a licensing and stock purchase agreement with an industry leader, Teva Pharmaceutical Industries, for the development of our novel anti-cancer compound, RX-3117,“ concluded Dr. Ahn.
“While 2009 was an important year for the validation of our pipeline drugs, we are even more excited about the next 12 to 18 months,” said Rick Soni, President and Chief Operating Officer of Rexahn. “Over this period, we expect to make significant clinical advances with our lead drugs, Serdaxin, Zoraxel and Archexin, and expand some of them into new indications. Further, we expect to add at least one clinical program in cancer and we will continue to seek out new partnerships across our clinical efforts, as there is significant interest among the bio-pharmaceutical industry in our intellectual property leadership."
Rexahn Goals for 2010:
Expand clinical development of Serdaxin to Parkinson’s disease. Current clinical studies demonstrate that Serdaxin prevents neuronal death, a disease mechanism implicated in many brain disorders, such as Parkinson’s and Alzheimer’s disease. In a Parkinson’s disease animal model, Serdaxin has proven to be a powerful neuroprotective agent and has significant potential as a next-generation drug for treatment that goes beyond the dopamine replacement schemes often used in current treatments. Additionally, a functional magnetic resonance imaging (fMRI) study exhibited stronger neuronal activity in dopamine and serotonin systems in Serdaxin-treated animals. Rexahn expects to begin a Phase II clinical trial in Parkinson’s disease in the second quarter of 2010.
Advance Serdaxin in Phase IIb clinical study for depression. Rexahn plans to advance Serdaxin in a Phase IIb clinical trial in depression. In October 2009 Rexahn reported top-line Phase IIa clinical results for Serdaxin for MDD. The study demonstrated that patients ages 18-65 with MDD exhibited clinically meaningful improvement over baseline in symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Serdaxin exhibited an onset of action in less than two weeks and was found to be safe and well tolerated, without any of the serious side effects often linked to currently marketed antidepressant drugs.
Advance clinical development of Zoraxel for sexual dysfunction. In the first half of 2010, Rexahn expects to submit a protocol to the U.S. Food and Drug Administration (FDA) for a Zoraxel Phase IIb clinical study in sexual dysfunction. In May 2009 Rexahn announced data from a Phase IIa clinical study demonstrating Zoraxel’s potential as an effective, new treatment of erectile dysfunction (ED) and as a safer alternative to currently marketed drugs for ED. The double blind, randomized, placebo-controlled, dose ranging study found that human subjects treated with Zoraxel demonstrated improved erectile function as measured by changes over the International Index of Erectile Function (IIEF) baseline score within the 8-week treatment period.
Continue clinical development of Archexin for the treatment of pancreatic cancer. Archexin is a first in class, potent Akt protein kinase inhibitor with potential utility to inhibit cancer cell survival and proliferation, angiogenesis, and drug resistance and is currently being studied in Phase II clinical trials in pancreatic cancer. Rexahn expects to complete these trials by the end of 2010. In previous clinical studies, Archexin has demonstrated an excellent human safety profile, with fatigue being the only noticeable side effect. Archexin has FDA Orphan drug designation for five different cancer types, including renal cell carcinoma, glioblastoma, pancreatic, stomach and ovarian cancers.
Initiate clinical program for RX-3117. Rexahn and partner Teva Pharmaceutical Industries are co-developing novel anti-cancer compound, RX-3117, for the treatment of cancer, in particular, gemcitabine-resistant lung cancer. RX-3117 has shown potent anti-tumor effects in xenograft human tumor models. Preclinical studies have revealed the compound’s high bioavailability and superior safety profile to gemcitabine, which is the current first-line therapy for pancreatic and other cancers. Rexahn and Teva expect to begin human clinical trials for RX-3117 in Q4 2010.
Form new partnerships. Rexahn seeks to form new product collaborations in addition to the partnership with Teva Pharmaceutical Industries; scientific platform alliances to maximize the utility of the Company’s three powerful discovery platforms; and research collaborations to further expand the pipeline candidates.
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2010.
“With our advancing clinical programs and robust pipeline of compounds for cancers and CNS-based disorders, such as Parkinson’s, Alzheimer’s, depression and sexual dysfunction, Rexahn is extremely well positioned to lead in the development of novel therapeutics for these disorders,” said Dr. Chang Ahn, CEO of Rexahn. “We look forward to continuing to expand our clinical programs and reporting data in 2010, bringing us closer to helping these patients in need.”
"These goals build on our successes in 2009, during which we announced positive clinical results for two of our lead clinical drug candidates, Serdaxin in Major Depressive Disorder (MDD) and Zoraxel for male sexual dysfunction, and we entered into a licensing and stock purchase agreement with an industry leader, Teva Pharmaceutical Industries, for the development of our novel anti-cancer compound, RX-3117,“ concluded Dr. Ahn.
“While 2009 was an important year for the validation of our pipeline drugs, we are even more excited about the next 12 to 18 months,” said Rick Soni, President and Chief Operating Officer of Rexahn. “Over this period, we expect to make significant clinical advances with our lead drugs, Serdaxin, Zoraxel and Archexin, and expand some of them into new indications. Further, we expect to add at least one clinical program in cancer and we will continue to seek out new partnerships across our clinical efforts, as there is significant interest among the bio-pharmaceutical industry in our intellectual property leadership."
Rexahn Goals for 2010:
Expand clinical development of Serdaxin to Parkinson’s disease. Current clinical studies demonstrate that Serdaxin prevents neuronal death, a disease mechanism implicated in many brain disorders, such as Parkinson’s and Alzheimer’s disease. In a Parkinson’s disease animal model, Serdaxin has proven to be a powerful neuroprotective agent and has significant potential as a next-generation drug for treatment that goes beyond the dopamine replacement schemes often used in current treatments. Additionally, a functional magnetic resonance imaging (fMRI) study exhibited stronger neuronal activity in dopamine and serotonin systems in Serdaxin-treated animals. Rexahn expects to begin a Phase II clinical trial in Parkinson’s disease in the second quarter of 2010.
Advance Serdaxin in Phase IIb clinical study for depression. Rexahn plans to advance Serdaxin in a Phase IIb clinical trial in depression. In October 2009 Rexahn reported top-line Phase IIa clinical results for Serdaxin for MDD. The study demonstrated that patients ages 18-65 with MDD exhibited clinically meaningful improvement over baseline in symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Serdaxin exhibited an onset of action in less than two weeks and was found to be safe and well tolerated, without any of the serious side effects often linked to currently marketed antidepressant drugs.
Advance clinical development of Zoraxel for sexual dysfunction. In the first half of 2010, Rexahn expects to submit a protocol to the U.S. Food and Drug Administration (FDA) for a Zoraxel Phase IIb clinical study in sexual dysfunction. In May 2009 Rexahn announced data from a Phase IIa clinical study demonstrating Zoraxel’s potential as an effective, new treatment of erectile dysfunction (ED) and as a safer alternative to currently marketed drugs for ED. The double blind, randomized, placebo-controlled, dose ranging study found that human subjects treated with Zoraxel demonstrated improved erectile function as measured by changes over the International Index of Erectile Function (IIEF) baseline score within the 8-week treatment period.
Continue clinical development of Archexin for the treatment of pancreatic cancer. Archexin is a first in class, potent Akt protein kinase inhibitor with potential utility to inhibit cancer cell survival and proliferation, angiogenesis, and drug resistance and is currently being studied in Phase II clinical trials in pancreatic cancer. Rexahn expects to complete these trials by the end of 2010. In previous clinical studies, Archexin has demonstrated an excellent human safety profile, with fatigue being the only noticeable side effect. Archexin has FDA Orphan drug designation for five different cancer types, including renal cell carcinoma, glioblastoma, pancreatic, stomach and ovarian cancers.
Initiate clinical program for RX-3117. Rexahn and partner Teva Pharmaceutical Industries are co-developing novel anti-cancer compound, RX-3117, for the treatment of cancer, in particular, gemcitabine-resistant lung cancer. RX-3117 has shown potent anti-tumor effects in xenograft human tumor models. Preclinical studies have revealed the compound’s high bioavailability and superior safety profile to gemcitabine, which is the current first-line therapy for pancreatic and other cancers. Rexahn and Teva expect to begin human clinical trials for RX-3117 in Q4 2010.
Form new partnerships. Rexahn seeks to form new product collaborations in addition to the partnership with Teva Pharmaceutical Industries; scientific platform alliances to maximize the utility of the Company’s three powerful discovery platforms; and research collaborations to further expand the pipeline candidates.
Rexahn Pharmaceuticals Submits Serdaxin® Phase II Protocol to FDA for Parkinson’s Disease
2010-04-05 08:00 ET - News Release
ROCKVILLE, Md. -- (Business Wire)
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson’s disease (PD).
“Serdaxin has demonstrated an ability to prevent neuronal deaths in PD models, and the drug’s positive Phase IIa results in depression further enhance its promise as a treatment for PD,” said Rexahn Chief Executive Officer, Dr. Chang Ahn. “Although there are currently various treatment options for PD, a meaningful cure is overdue. Based on Serdaxin’s novel action as a dual serotonin and dopamine enhancer, we believe it has the potential to be the first drug of its kind to target both the classic symptoms of PD and treat the depression so often associated with this disease.”
The Phase II study will assess Serdaxin’s efficacy as a treatment for Parkinson’s disease in approximately 300 subjects. The planned double blind, randomized, placebo-controlled trial will include the Unified Parkinson’s Disease Rating Scale (UPDRS) and quality of life instruments as study endpoints and will be conducted at multiple sites.
Rexahn also has formed a Parkinson’s Scientific Advisory Board (SAB) composed of leading medical researchers in the field of neurology who will advise on the design and development of the Serdaxin clinical trials. Commenting on the protocol submission, Dr. William Weiner, Chairman of the SAB, and head of the Maryland Parkinson’s Disease and Movement Disorders Center, and Professor and Chair of the Department of Neurology at the University of Maryland School of Medicine, said, "We believe that Serdaxin's properties in animal models open exciting possibilities as a new treatment for patients with PD. All the members of the SAB will be actively engaged in Serdaxin's clinical development, which we hope will further establish the drug's efficacy in treating PD."
About Serdaxin®
Serdaxin® is a potential market-leading CNS neuroprotective agent and antidepressant. Rexahn is currently investigating Serdaxin as a treatment for depression in Phase II clinical trials. Serdaxin may achieve greater and broader therapeutic coverage and appears to have no serious side effects such as nausea, vomiting, insomnia, weight gain, sexual dysfunction, cognitive deficit or motor impairment that are linked to existing antidepressant drugs. Serdaxin has a well-established, excellent human safety profile. In preclinical studies, Serdaxin had onset of action in less than two days. Based on its novel mechanism as a dual serotonin and dopamine enhancer, it is a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses, such as Parkinson’s disease (PD). Serdaxin has the potential to address both non-motor and motor events of PD by serving as a neuroprotective agent and addressing loss of dopaminergic neurons that lead to loss of control of movements; and further, enhancing serotonin and dopamine levels that are involved in depression and mood disorders. Rexahn has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson’s disease, Alzheimer’s disease and neurodegenerative illnesses, neuroprotection and biodefense uses.
About Parkinson’s Disease
Parkinson’s disease (PD) is the most common movement disorder, affecting more than 5 million patients worldwide. Age is the most important risk factor for PD, and the aging world population is expected to push the number of the afflicted to over 10 million by 2030. In addition, its chronic and debilitating nature warrants high socio-economic impacts. PD is characterized by the progressive loss of dopaminergic neurons in the brain. The resulting dopamine depletion leads to its cardinal motor symptoms, such as rigidity (muscle stiffness), bradykinesia (slowing of movement), postural instability and resting tremor. These impairments are accompanied by non-motor disabilities, including dementia, depression, and sleep disturbance. The current standard treatment options target the dopaminergic pathway, either by supplementing the molecule or stimulating dopamine receptors (binding partners of dopamine). While these strategies ameliorate symptoms in early stages, they become less effective over the course of the disease. In addition, dopamine therapies fail to tackle the underlying causes of the disease, and therefore, do not slow the progression of PD or extend the life expectancy of patients. Serdaxin is a new class of CNS disorder therapeutics that has prevented neuronal deaths in PD models. In contrast to other PD drugs, Serdaxin directly targets the disease mechanism by slowing or halting the progression of the disease, fulfilling unmet needs in Parkinson’s disease treatment.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
Contacts:
Rexahn Pharmaceuticals, Inc.
Investor Relations
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com
Source: Rexahn Pharmaceuticals, Inc.
2010-04-05 08:00 ET - News Release
ROCKVILLE, Md. -- (Business Wire)
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson’s disease (PD).
“Serdaxin has demonstrated an ability to prevent neuronal deaths in PD models, and the drug’s positive Phase IIa results in depression further enhance its promise as a treatment for PD,” said Rexahn Chief Executive Officer, Dr. Chang Ahn. “Although there are currently various treatment options for PD, a meaningful cure is overdue. Based on Serdaxin’s novel action as a dual serotonin and dopamine enhancer, we believe it has the potential to be the first drug of its kind to target both the classic symptoms of PD and treat the depression so often associated with this disease.”
The Phase II study will assess Serdaxin’s efficacy as a treatment for Parkinson’s disease in approximately 300 subjects. The planned double blind, randomized, placebo-controlled trial will include the Unified Parkinson’s Disease Rating Scale (UPDRS) and quality of life instruments as study endpoints and will be conducted at multiple sites.
Rexahn also has formed a Parkinson’s Scientific Advisory Board (SAB) composed of leading medical researchers in the field of neurology who will advise on the design and development of the Serdaxin clinical trials. Commenting on the protocol submission, Dr. William Weiner, Chairman of the SAB, and head of the Maryland Parkinson’s Disease and Movement Disorders Center, and Professor and Chair of the Department of Neurology at the University of Maryland School of Medicine, said, "We believe that Serdaxin's properties in animal models open exciting possibilities as a new treatment for patients with PD. All the members of the SAB will be actively engaged in Serdaxin's clinical development, which we hope will further establish the drug's efficacy in treating PD."
About Serdaxin®
Serdaxin® is a potential market-leading CNS neuroprotective agent and antidepressant. Rexahn is currently investigating Serdaxin as a treatment for depression in Phase II clinical trials. Serdaxin may achieve greater and broader therapeutic coverage and appears to have no serious side effects such as nausea, vomiting, insomnia, weight gain, sexual dysfunction, cognitive deficit or motor impairment that are linked to existing antidepressant drugs. Serdaxin has a well-established, excellent human safety profile. In preclinical studies, Serdaxin had onset of action in less than two days. Based on its novel mechanism as a dual serotonin and dopamine enhancer, it is a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses, such as Parkinson’s disease (PD). Serdaxin has the potential to address both non-motor and motor events of PD by serving as a neuroprotective agent and addressing loss of dopaminergic neurons that lead to loss of control of movements; and further, enhancing serotonin and dopamine levels that are involved in depression and mood disorders. Rexahn has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson’s disease, Alzheimer’s disease and neurodegenerative illnesses, neuroprotection and biodefense uses.
About Parkinson’s Disease
Parkinson’s disease (PD) is the most common movement disorder, affecting more than 5 million patients worldwide. Age is the most important risk factor for PD, and the aging world population is expected to push the number of the afflicted to over 10 million by 2030. In addition, its chronic and debilitating nature warrants high socio-economic impacts. PD is characterized by the progressive loss of dopaminergic neurons in the brain. The resulting dopamine depletion leads to its cardinal motor symptoms, such as rigidity (muscle stiffness), bradykinesia (slowing of movement), postural instability and resting tremor. These impairments are accompanied by non-motor disabilities, including dementia, depression, and sleep disturbance. The current standard treatment options target the dopaminergic pathway, either by supplementing the molecule or stimulating dopamine receptors (binding partners of dopamine). While these strategies ameliorate symptoms in early stages, they become less effective over the course of the disease. In addition, dopamine therapies fail to tackle the underlying causes of the disease, and therefore, do not slow the progression of PD or extend the life expectancy of patients. Serdaxin is a new class of CNS disorder therapeutics that has prevented neuronal deaths in PD models. In contrast to other PD drugs, Serdaxin directly targets the disease mechanism by slowing or halting the progression of the disease, fulfilling unmet needs in Parkinson’s disease treatment.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
Contacts:
Rexahn Pharmaceuticals, Inc.
Investor Relations
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com
Source: Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals to Present at NASDAQ MarketSite
2010-04-07 08:00 ET - News Release
Invite Media and Investors to the MarketSite, New York City, Tuesday, April 13, 2010, 12:30pm EDT
ROCKVILLE, Md. -- (Business Wire)
Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that Dr. Chang Ahn, Rexahn’s Chief Executive Officer, will present at the NASDAQ MarketSite in Times Square, New York City, NY on Tuesday, April 13, 2010 at 12:30 PM EDT.
Dr. Ahn will discuss Rexhan’s important corporate developments in conjunction with a simultaneously issued press release.
Investors and media are welcome to attend and RSVP to:
Christi Flood
MUNCmedia
Communications & Marketing Manager
212-699-0999
Christina.flood@muncmedia.com
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
Contacts:
Investor Relations:
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Media and Press Relations:
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com
Source: Rexahn Pharmaceuticals, Inc.
2010-04-07 08:00 ET - News Release
Invite Media and Investors to the MarketSite, New York City, Tuesday, April 13, 2010, 12:30pm EDT
ROCKVILLE, Md. -- (Business Wire)
Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that Dr. Chang Ahn, Rexahn’s Chief Executive Officer, will present at the NASDAQ MarketSite in Times Square, New York City, NY on Tuesday, April 13, 2010 at 12:30 PM EDT.
Dr. Ahn will discuss Rexhan’s important corporate developments in conjunction with a simultaneously issued press release.
Investors and media are welcome to attend and RSVP to:
Christi Flood
MUNCmedia
Communications & Marketing Manager
212-699-0999
Christina.flood@muncmedia.com
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
Contacts:
Investor Relations:
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Media and Press Relations:
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com
Source: Rexahn Pharmaceuticals, Inc.
unglaublich was hier abgeht...
nächster halt- 4 dollar
nächster halt- 4 dollar
Rexahn's Zoraxel™ and Serdaxin® Close To Big Pharma Deals
2010-06-22 09:21 ET - News Release
The latest analyst report by Goldman Small-Cap Research lists four reasons why the stock price of this small-cap biotech should be higher and we couldn't agree more. Shares of Rexahn Pharmaceuticals, Inc. (AMEX: RNN) continue to scream "buy," especially at their current prices. Recently, the company hired Fred Frank as a consultant to the company. Anyone who knows about Mr. Frank will tell you that this is a tell that the company is getting close to final negotiations for licensing of either or both of their Phase IIb drugs, Zoraxel™ (sexual disfunction) and Serdaxin® (for depression). Mr. Frank is probably the most well known major pharma banker over the last 25 yrs. The fact that he is working with Rexahn is also significant because he rarely works for pharma companies of their size. Sources tell us that Mr. Frank was compelled to do this deal because both drugs have tremendous breakthrough potential and "each has blockbuster written all over them." Interestingly, the company has publicly stated that they were actively engaged with at least six different large pharmaceutical companies the last time we heard from them at their Nasdaq Market Site press conference. Since then, biotech investors have seen shares drop down to the current levels- still at nearly double the price it was when BioMedReports recommended the stock to it's subscribers. At that time a few months ago, RNN was mostly an undiscovered biotech trading at $.70 levels. Now many analysts believe that Mr. Frank's ability to negotiate with some of top pharma CEOs has increased the odds of a substantial licensing deal for the two drugs and that the deal should be announced sometime between now and year end. Wall Street believes the potential deal to be nearly $1 billion and to be made up of milestone payments and double digit royalties with at least $50 million upfront. Company officials have said they expect the deal to be valued at 3 to 4 times the value of the current deal they have with Teva Pharmaceutical Industries for an experimental cancer-fighting compound; RX-3117, a small molecule, new chemical entity nucleoside compound being developed by Rexahn for treating a broad range of cancers. That drug was only in the pre-clinical stages when it was licensed by Teva, but the data was compelling enough to cause Teva to invest nearly $4 million in Rexahn (at 20 percent over market), pay for all development costs and to take on $200 million in milestone payments thus far. The Zoraxel™ and Serdaxin® drugs are substantially further along in development (Phase IIb versus preclinical). Teva is also expected to pay a $4 million milestone payment when RX-3117 moves into Phase I in the coming months (company officials expect that event to take place during the last quarter of this year). Also making headlines recently, Boehringer's "female Viagra" drug Flibanserin was voted down by an FDA advisory panel because it “failed to demonstrate a statistically significant improvement” in sexual desire in two trials. Flibanserin, an oral treatment that was originally developed as an antidepressant, affects levels of serotonin and other chemicals in the brain, but reviewers were concerned about Flibanserin's side-effects. Meanwhile, RNN's Zoraxel™ acts in a similar fashion, and could fill a key a role the underserved female sexual disfunction market- plus it has not shown significant side effects. The fact that Flibanserin seemed to work only by increasing serotonin alone can be seen as proof that Zoraxel™ is on right track here because it simultaneously increases dopamine levels as well. In addition, Boehringer's drug had to be taken 30 days before sexual activity while Rexahn drug needs only to be taken 30 minutes before sexual activity. The attention the Boehringer drug has received has heightened interest from Pfizer (NYSE: PFE), Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly & Co (NYSE: LLY) as to the potential market size of the drug and it has more clearly shown the industry what the FDA expects. RNN's Zoraxel™ seems to more clearly "fit the bill" and insiders and analysts are both hopeful that these companies are now more primed to push a deal. Once again, it appears RNN is undervalued and poised to rise.
2010-06-22 09:21 ET - News Release
The latest analyst report by Goldman Small-Cap Research lists four reasons why the stock price of this small-cap biotech should be higher and we couldn't agree more. Shares of Rexahn Pharmaceuticals, Inc. (AMEX: RNN) continue to scream "buy," especially at their current prices. Recently, the company hired Fred Frank as a consultant to the company. Anyone who knows about Mr. Frank will tell you that this is a tell that the company is getting close to final negotiations for licensing of either or both of their Phase IIb drugs, Zoraxel™ (sexual disfunction) and Serdaxin® (for depression). Mr. Frank is probably the most well known major pharma banker over the last 25 yrs. The fact that he is working with Rexahn is also significant because he rarely works for pharma companies of their size. Sources tell us that Mr. Frank was compelled to do this deal because both drugs have tremendous breakthrough potential and "each has blockbuster written all over them." Interestingly, the company has publicly stated that they were actively engaged with at least six different large pharmaceutical companies the last time we heard from them at their Nasdaq Market Site press conference. Since then, biotech investors have seen shares drop down to the current levels- still at nearly double the price it was when BioMedReports recommended the stock to it's subscribers. At that time a few months ago, RNN was mostly an undiscovered biotech trading at $.70 levels. Now many analysts believe that Mr. Frank's ability to negotiate with some of top pharma CEOs has increased the odds of a substantial licensing deal for the two drugs and that the deal should be announced sometime between now and year end. Wall Street believes the potential deal to be nearly $1 billion and to be made up of milestone payments and double digit royalties with at least $50 million upfront. Company officials have said they expect the deal to be valued at 3 to 4 times the value of the current deal they have with Teva Pharmaceutical Industries for an experimental cancer-fighting compound; RX-3117, a small molecule, new chemical entity nucleoside compound being developed by Rexahn for treating a broad range of cancers. That drug was only in the pre-clinical stages when it was licensed by Teva, but the data was compelling enough to cause Teva to invest nearly $4 million in Rexahn (at 20 percent over market), pay for all development costs and to take on $200 million in milestone payments thus far. The Zoraxel™ and Serdaxin® drugs are substantially further along in development (Phase IIb versus preclinical). Teva is also expected to pay a $4 million milestone payment when RX-3117 moves into Phase I in the coming months (company officials expect that event to take place during the last quarter of this year). Also making headlines recently, Boehringer's "female Viagra" drug Flibanserin was voted down by an FDA advisory panel because it “failed to demonstrate a statistically significant improvement” in sexual desire in two trials. Flibanserin, an oral treatment that was originally developed as an antidepressant, affects levels of serotonin and other chemicals in the brain, but reviewers were concerned about Flibanserin's side-effects. Meanwhile, RNN's Zoraxel™ acts in a similar fashion, and could fill a key a role the underserved female sexual disfunction market- plus it has not shown significant side effects. The fact that Flibanserin seemed to work only by increasing serotonin alone can be seen as proof that Zoraxel™ is on right track here because it simultaneously increases dopamine levels as well. In addition, Boehringer's drug had to be taken 30 days before sexual activity while Rexahn drug needs only to be taken 30 minutes before sexual activity. The attention the Boehringer drug has received has heightened interest from Pfizer (NYSE: PFE), Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly & Co (NYSE: LLY) as to the potential market size of the drug and it has more clearly shown the industry what the FDA expects. RNN's Zoraxel™ seems to more clearly "fit the bill" and insiders and analysts are both hopeful that these companies are now more primed to push a deal. Once again, it appears RNN is undervalued and poised to rise.
Die letzten Analystenbericht von Goldman Small-Cap Research nennt vier Gründe, warum der Aktienkurs des Small-Cap-Biotech höher sein sollte und wir konnten nicht mehr zustimmen. Die Aktien der Rexahn Pharmaceuticals, weiterhin Inc. (Amex: RNN) zu schreien "kaufen", vor allem in ihrer derzeitigen Preisen. Kürzlich stellte das Unternehmen Fred Frank als Berater für das Unternehmen. Wer über Herrn Frank kennt, der weiß, dass dies eine zu sagen, dass das Unternehmen liegt in der Nähe abschließenden Verhandlungen für die Lizenzierung von einem oder beiden der Phase IIb Drogen, Zoraxel ™ (sexuelle Funktionsstörung) und Serdaxin ® (gegen Depressionen) bekommen wird. Herr Frank ist wahrscheinlich die bekannteste großen Pharma Bankier über die letzten 25 Jahre. Die Tatsache, dass er mit Rexahn Arbeitsbedingungen ist auch bedeutsam, weil er arbeitet selten für Pharma-Unternehmen von ihrer Größe. Quellen sagen uns, dass Herr Frank gezwungen war, dieses Geschäft zu tun, weil beide Medikamente gewaltigen Durchbruch Potential haben und "jeder Blockbuster hat alle über sie geschrieben." Interessanterweise hat sich das Unternehmen öffentlich erklärt, dass sie aktiv wurden mit mindestens sechs verschiedenen großen Pharmaunternehmen wir das letzte Mal von ihnen gehört zu ihren Nasdaq Market Pressekonferenz vor Ort engagiert. Seitdem haben Biotech-Investoren gesehen Aktie bis auf den derzeitigen Niveau noch-Drop auf fast das Doppelte des Preises war es, als BioMedReports die Aktie empfohlen, es ist Abonnenten. Damals vor ein paar Monaten wurde RNN meist ein unentdecktes Biotech-Handel bei 0,70 $ Ebenen. Nun haben viele Analysten glauben, dass Mr. Frank's Fähigkeit, mit einigen der besten CEOs verhandeln Pharma hat die Chancen für einen wesentlichen Lizenzvertrag für die beiden Medikamente erhöht und dass das Geschäft irgendwann zwischen jetzt und soll Ende des Jahres bekannt gegeben. Wall Street hält das Potenzial viel zu knapp $ 1000000000 und sich aus Meilensteinzahlungen erfolgen und Lizenzgebühren in zweistelliger Höhe, muss mit mindestens $ 50.000.000 im Voraus. Unternehmen haben die Beamten sagten, sie erwarten, dass der Deal auf 3 bis 4-fachen Wert des aktuellen Deal bewertet sie mit Teva Pharmaceutical Industries für eine experimentelle Krebs-Bekämpfung Verbindung; RX-3117, ein kleines Molekül, neue chemische Einheit Nukleosid-Verbindung wird entwickelt von Rexahn für die Behandlung einer breiten Palette von Krebsarten. Das Medikament wurde erst im Stadium der präklinischen Entwicklung, wenn sie von Teva lizenziert wurde, aber die Daten waren überzeugend genug, um Ursache Teva auf fast $ 4.000.000 in Rexahn investieren (bei 20 Prozent gegenüber dem Markt), zahlen für alle Entwicklungskosten und die Übernahme von $ 200,000,000 in Meilensteinzahlungen bisher. Die Zoraxel ™ und ® Serdaxin Drogen sind wesentlich weiter in der Entwicklung (Phase IIb versus präklinischen). Teva wird auch erwartet, dass 4.000.000 $ Meilensteinzahlung beim RX-3117 in Phase I bewegt sich in den kommenden Monaten (Firma Beamten erwarten, dass bei zu Ort im letzten Quartal dieses Jahres stattfinden bezahlen). Auch vor kurzem für Schlagzeilen, Boehringer's "Female Viagra" drug Flibanserin wurde durch ein FDA-Expertengremium gestimmt, weil er "nicht zu einer statistisch signifikanten Verbesserung" in das sexuelle Verlangen in zwei Studien zeigen. Flibanserin, eine orale Therapie, die ursprünglich als Antidepressivum entwickelt wurde, wirkt Serotonin und andere Chemikalien im Gehirn, sondern Rezensenten zeigten sich besorgt über Nebenwirkungen Flibanserin die Auswirkungen. Inzwischen agiert das RNN Zoraxel ™ in ähnlicher Weise, und könnte eine wichtige Rolle füllen die weiblichen sexuellen Funktionsstörung unterversorgten Markt-plus hat es keine signifikanten Nebenwirkungen gezeigt. Die Tatsache, dass Flibanserin nur Arbeiten durch die Erhöhung Serotonin allein schien, als Beweis dafür gesehen werden, dass Zoraxel ™ am richtigen Weg ist hier, weil es erhöht gleichzeitig Dopaminniveaus sowie. Darüber hinaus hatte Boehringer-Medikament zu treffenden 30 Tage vor der sexuellen Aktivität, während Rexahn Medikament braucht nur 30 Minuten vor sexueller Aktivität. Die Aufmerksamkeit der Boehringer Medikament erhalten hat, hat das Interesse von Pfizer (NYSE: PFE) erhöht, Bristol-Myers Squibb (NYSE: BMY) und Eli Lilly & Co (NYSE: LLY) als auf den potenziellen Markt Größe der Droge, und es hat mehr deutlich gezeigt, der Industrie, was die FDA erwartet. RNN's Zoraxel ™ scheint deutlicher "passen die Rechnung" und Insidern und Analysten sind beide zuversichtlich, dass diese Unternehmen nun mehr grundiert, ein Abkommen zu drängen. Wieder einmal scheint es, RNN unterbewertet ist und bereit zu steigen.
Antwort auf Beitrag Nr.: 40.697.404 von erdo1 am 12.12.10 22:12:07Ist hier noch Leben drinnen, jemand investiert?
Antwort auf Beitrag Nr.: 40.810.669 von CharlesBarkley2007 am 06.01.11 13:51:10JO !
Antwort auf Beitrag Nr.: 40.810.669 von CharlesBarkley2007 am 06.01.11 13:51:10SmarTrend Watching for Potential Rebound in Shares of Rexahn Pharmaceuticals After 1.74% Loss (RNN)
Written on Mon, 01/03/2011 - 3:57am
By Sarah Hashim-Waris
Rexahn Pharmaceuticals (AMEX:RNN) traded in a range yesterday that spanned from a low of $1.11 to a high of $1.16. Yesterday, the shares fell 1.74%, which took the trading range below the 3-day low of $1.12 on volume of 326,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean revision.
Shares of Rexahn Pharmaceuticals are currently trading below their 200-day moving average (MA) of $1.40 and should find support at their 50-day MA of $1.10. Look for the MA to provide resistance for a short-term rebound in the shares.
SmarTrend currently has shares of Rexahn Pharmaceuticals in an Downtrend and issued the Downtrend alert on August 10, 2010 at $1.28. The stock has fallen 10.5% since the Downtrend alert was issued.
SmarTrend expects the share price to rebound toward the $1.13 resistance level. Afterwards, we expect it to move downward with its peers in the SmarTrend Biotechnology industry.
http://www.mysmartrend.com/news-briefs/news-watch/smartrend-…
Written on Mon, 01/03/2011 - 3:57am
By Sarah Hashim-Waris
Rexahn Pharmaceuticals (AMEX:RNN) traded in a range yesterday that spanned from a low of $1.11 to a high of $1.16. Yesterday, the shares fell 1.74%, which took the trading range below the 3-day low of $1.12 on volume of 326,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean revision.
Shares of Rexahn Pharmaceuticals are currently trading below their 200-day moving average (MA) of $1.40 and should find support at their 50-day MA of $1.10. Look for the MA to provide resistance for a short-term rebound in the shares.
SmarTrend currently has shares of Rexahn Pharmaceuticals in an Downtrend and issued the Downtrend alert on August 10, 2010 at $1.28. The stock has fallen 10.5% since the Downtrend alert was issued.
SmarTrend expects the share price to rebound toward the $1.13 resistance level. Afterwards, we expect it to move downward with its peers in the SmarTrend Biotechnology industry.
http://www.mysmartrend.com/news-briefs/news-watch/smartrend-…
Antwort auf Beitrag Nr.: 40.810.810 von Aktientitan am 06.01.11 14:07:05Pre-Market Last: 1,52 USD
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…
Antwort auf Beitrag Nr.: 40.810.838 von Aktientitan am 06.01.11 14:09:00und gibt es irgendwelche spekulationen deinerseits? wenn vorbörslich mehr stücke über das parkett gehen als an den meisten anderen tagen im ganzen handel, dann ist doch was im busch... oder sind es nur menschen, die glauben dass etwas im busch ist?
hat schon wieder geraschlt, im Busch.
Solider Anstieg, was will man mehr?
heute hier n fetter Anstieg, noch jemand dabei?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,75 | |
| -0,35 | |
| -1,64 | |
| -1,91 | |
| -1,47 | |
| -0,21 | |
| -2,99 | |
| -0,77 | |
| 0,00 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 204 | ||
| 190 | ||
| 146 | ||
| 69 | ||
| 32 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 25 |
